Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2017 | The pivotal ZUMA-1 trial for NHL

Sattva Neelapu • 14 Jun 2017
ICML 2017
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Axicabtagene ciloleucel CAR-T
ZUMA-1

Sattva Neelapu, MD from the MD Anderson Cancer Center, Houston, TX gives an overview of his work on the development of KTE-C19, a CAR T-cell developed for relapsed/refractory non-Hodgkin lymphoma (NHL). Here, he provides a detailed explanation of the development of the ZUMA-1 trial (NCT02348216). The results of the trial have been promising in terms of overall and complete response rates as well as remission. This interview was recorded at the International Conference on Malignant Lymphoma (ICML) 2017 in Lugano, Switzerland.

More from Sattva Neelapu

0:42
Next steps with ADI-001
Sattva Neelapu • 5 Jun 2022
2:06
ZUMA-12: axi-cel as first-line therapy in high-risk large B-cell lymphoma
Sattva Neelapu • 5 Jun 2022
3:24
ADI-001: anti-CD20 CAR-engineered allogeneic γδ T cells in adults with B-cell malignancies
Sattva Neelapu • 5 Jun 2022
2:43
Long-term follow-up results of ZUMA-5: axi-cel in patients with R/R indolent NHL
Sattva Neelapu • 12 Dec 2021

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals